Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2016

01.02.2016 | Thoracic Oncology

Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis

verfasst von: Hariruk Yodying, MD, Akihisa Matsuda, MD, Masao Miyashita, MD, Satoshi Matsumoto, MD, Nobuyuki Sakurazawa, MD, Marina Yamada, PhD, Eiji Uchida, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been reported to predict oncologic outcomes in patients with various types of cancer. However, their prognostic value in patients with esophageal cancer is unclear. In this meta-analysis, we evaluated the prognostic significance of NLR and PLR in esophageal cancer patients.

Methods

We performed comprehensive searches of electronic databases to identify studies that evaluated the prognostic impact of pretreatment NLR and PLR in esophageal cancer patients. The end points were overall survival (OS), disease-free survival, and clinicopathologic parameters. A meta-analysis using random-effects models was performed to calculate hazard ratios (HRs) or odds ratios with 95 % confidence intervals (CIs).

Results

Seven retrospective, observational, cohort studies involving 1540 patients were included. All seven studies evaluated NLR, and four evaluated PLR. Both high NLR (HR 1.40, 95 % CI 1.08–1.81, P = 0.01) and high PLR (HR 1.59, 95 % CI 1.14–2.21, P = 0.006) were significantly predictive of poorer OS. NLR was not a significant predictor of disease-free survival. High PLR (HR 1.85, 95 % CI 1.50–2.28, P < 0.00001) but not NLR was significantly predictive of poorer OS in a subgroup of patients who underwent curative surgery without neoadjuvant chemoradiation. Both high NLR and high PLR were significantly associated with deeper tumor invasion and lymph node metastasis.

Conclusions

NLR and PLR are associated with tumor progression and are predictive of poorer survival in patients with esophageal cancer. These ratios may thus help to inform treatment decisions and predict treatment outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am. 2002;82:729–46.PubMedCrossRef Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am. 2002;82:729–46.PubMedCrossRef
2.
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.PubMedCrossRef Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.PubMedCrossRef
3.
Zurück zum Zitat Paul S, Altorki N. Outcomes in the management of esophageal cancer. J Surg Oncol. 2014;110:599–610.PubMedCrossRef Paul S, Altorki N. Outcomes in the management of esophageal cancer. J Surg Oncol. 2014;110:599–610.PubMedCrossRef
4.
Zurück zum Zitat Rice TW, Rusch VW, Ishwaran H, Blackstone EH; Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer staging manuals. Cancer. 2010;116:3763–73.PubMedCrossRef Rice TW, Rusch VW, Ishwaran H, Blackstone EH; Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer staging manuals. Cancer. 2010;116:3763–73.PubMedCrossRef
5.
Zurück zum Zitat Blanchard P, Quero L, Hennequin C. Prognostic and predictive factors of oesophageal carcinoma. Bull Cancer. 2009;96:379–89.PubMed Blanchard P, Quero L, Hennequin C. Prognostic and predictive factors of oesophageal carcinoma. Bull Cancer. 2009;96:379–89.PubMed
6.
Zurück zum Zitat Chen M, Cai E, Huang J, Yu P, Li K. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:1126–34.PubMedCrossRef Chen M, Cai E, Huang J, Yu P, Li K. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:1126–34.PubMedCrossRef
7.
Zurück zum Zitat Wang XL, Zhang CM, Shi LY, Yu HP, Xu SQ. Significance of p53 gene mutation and P53 protein expression abnormality on the prognosis of esophageal cancer: a meta-analysis study. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25:769–74.PubMed Wang XL, Zhang CM, Shi LY, Yu HP, Xu SQ. Significance of p53 gene mutation and P53 protein expression abnormality on the prognosis of esophageal cancer: a meta-analysis study. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25:769–74.PubMed
9.
Zurück zum Zitat Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:58.PubMedPubMedCentralCrossRef Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:58.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204–12.PubMedCrossRef Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204–12.PubMedCrossRef
11.
Zurück zum Zitat Chen H, He J. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after radical resection of esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2014;36:294–7.PubMed Chen H, He J. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after radical resection of esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2014;36:294–7.PubMed
12.
Zurück zum Zitat Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet–lymphocyte ratio. J Gastrointest Surg. 2008;12:1422–8.PubMedCrossRef Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet–lymphocyte ratio. J Gastrointest Surg. 2008;12:1422–8.PubMedCrossRef
13.
Zurück zum Zitat Stotz M, Gerger A, Eisner F, Szkandera J, LoibnerH, Ress AL et al. Increased neutrophil–lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416–21.PubMedPubMedCentralCrossRef Stotz M, Gerger A, Eisner F, Szkandera J, LoibnerH, Ress AL et al. Increased neutrophil–lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416–21.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35:1861–6.PubMedCrossRef Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35:1861–6.PubMedCrossRef
15.
Zurück zum Zitat Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Oncol Targets Ther. 2013;6:1605–12. Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Oncol Targets Ther. 2013;6:1605–12.
16.
Zurück zum Zitat Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med. 2011;2:879–85.PubMedPubMedCentral Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med. 2011;2:879–85.PubMedPubMedCentral
17.
Zurück zum Zitat Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18:3362–9.PubMedPubMedCentralCrossRef Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18:3362–9.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Xie X, Luo KJ, Hu Y, Wang JY, Chen J. Prognostic value of preoperative platelet–lymphocyte and neutrophil–lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. Dis Esophagus. 2014. doi:10.1111/dote.12296. Xie X, Luo KJ, Hu Y, Wang JY, Chen J. Prognostic value of preoperative platelet–lymphocyte and neutrophil–lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. Dis Esophagus. 2014. doi:10.​1111/​dote.​12296.
19.
Zurück zum Zitat Yoo EJ, Park JC, Kim EH, Park CH, Shim CN, Lee HJ et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. Dig Liver Dis. 2014;46:846–53.PubMedCrossRef Yoo EJ, Park JC, Kim EH, Park CH, Shim CN, Lee HJ et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. Dig Liver Dis. 2014;46:846–53.PubMedCrossRef
20.
Zurück zum Zitat Rashid F, Waraich N, Bhatti I, Saha S, Khan, RN, Ahmed J et al. A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol. 2010;8:1.PubMedPubMedCentralCrossRef Rashid F, Waraich N, Bhatti I, Saha S, Khan, RN, Ahmed J et al. A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol. 2010;8:1.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Tanoglu A, Karagoz E, Yiyit N, Berber U. Is combination of neutrophil to lymphocyte ratio and platelet lymphocyte ratio a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma? Oncol Targets Ther. 2014;7:433–4.CrossRef Tanoglu A, Karagoz E, Yiyit N, Berber U. Is combination of neutrophil to lymphocyte ratio and platelet lymphocyte ratio a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma? Oncol Targets Ther. 2014;7:433–4.CrossRef
22.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.PubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.PubMedCrossRef
24.
Zurück zum Zitat Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRef Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRef
27.
Zurück zum Zitat Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef
28.
Zurück zum Zitat Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMedCrossRef Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMedCrossRef
29.
Zurück zum Zitat Feng JF, Huang Y, Zhao Q, Chen QX. Clinical significance of preoperative neutrophil lymphocyte ratio versus platelet lymphocyte ratio in patients with small cell carcinoma of the esophagus. ScientificWorldJournal. 2013;2013:504365.PubMedPubMedCentral Feng JF, Huang Y, Zhao Q, Chen QX. Clinical significance of preoperative neutrophil lymphocyte ratio versus platelet lymphocyte ratio in patients with small cell carcinoma of the esophagus. ScientificWorldJournal. 2013;2013:504365.PubMedPubMedCentral
30.
Zurück zum Zitat Feng JF, Huang Y, Chen QX. The combination of platelet count and neutrophil lymphocyte ratio is a predictive factor in patients with esophageal squamous cell carcinoma. Transl Oncol. 2014;7:632–7.PubMedPubMedCentralCrossRef Feng JF, Huang Y, Chen QX. The combination of platelet count and neutrophil lymphocyte ratio is a predictive factor in patients with esophageal squamous cell carcinoma. Transl Oncol. 2014;7:632–7.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Ying HQ, Deng QW, He BS, Pan YQ, Wang F, Sun HL et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014;31:305.PubMedCrossRef Ying HQ, Deng QW, He BS, Pan YQ, Wang F, Sun HL et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014;31:305.PubMedCrossRef
32.
Zurück zum Zitat Zhang W, Yu C, Huang B, Zhou FL, Huang HD, Li Q. Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients. Oncol Lett. 2015;9:762–8.PubMedPubMedCentral Zhang W, Yu C, Huang B, Zhou FL, Huang HD, Li Q. Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients. Oncol Lett. 2015;9:762–8.PubMedPubMedCentral
33.
Zurück zum Zitat Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.PubMedCrossRef Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.PubMedCrossRef
34.
Zurück zum Zitat Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.PubMedCrossRef Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.PubMedCrossRef
35.
Zurück zum Zitat Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol. 2003;26:135–40.PubMedCrossRef Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol. 2003;26:135–40.PubMedCrossRef
36.
Zurück zum Zitat Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287–91.PubMedCrossRef Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287–91.PubMedCrossRef
37.
Zurück zum Zitat Guo T, Krzystanek M, Szallasi Z, Szallasi A. Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma. F1000Res. 2014;3:180.PubMedPubMedCentral Guo T, Krzystanek M, Szallasi Z, Szallasi A. Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma. F1000Res. 2014;3:180.PubMedPubMedCentral
38.
Zurück zum Zitat Zheng TL, Cao K, Liang C, Zhang K, Guo HZ, Li DP et al. Prognostic value of C-reactive protein in esophageal cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:8075–81.PubMedCrossRef Zheng TL, Cao K, Liang C, Zhang K, Guo HZ, Li DP et al. Prognostic value of C-reactive protein in esophageal cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:8075–81.PubMedCrossRef
39.
Zurück zum Zitat Huang XZ, Gao P, Sun JX, Song YX, Tsai CC, Liu J et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control. 2015;26:589–600.PubMedCrossRef Huang XZ, Gao P, Sun JX, Song YX, Tsai CC, Liu J et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control. 2015;26:589–600.PubMedCrossRef
41.
Zurück zum Zitat Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg. 1995;109:130–8.PubMedCrossRef Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg. 1995;109:130–8.PubMedCrossRef
42.
Zurück zum Zitat Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg. 2004;78:1177–83.PubMedCrossRef Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg. 2004;78:1177–83.PubMedCrossRef
43.
Zurück zum Zitat Zhang HL, Chen LQ, Liu RL, Shi YT, He M, Meng XL et al. The number of lymph node metastases influences survival and International Union Against Cancer tumor–node–metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus. 2010;23:53–8.PubMedCrossRef Zhang HL, Chen LQ, Liu RL, Shi YT, He M, Meng XL et al. The number of lymph node metastases influences survival and International Union Against Cancer tumor–node–metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus. 2010;23:53–8.PubMedCrossRef
44.
Zurück zum Zitat Cho JW, Choi SC, Jang JY, Shin SK, Choi KD, Lee JH et al. Lymph node metastases in esophageal carcinoma: an endoscopist’s view. Clin Endosc. 2014;47:523–9.PubMedPubMedCentralCrossRef Cho JW, Choi SC, Jang JY, Shin SK, Choi KD, Lee JH et al. Lymph node metastases in esophageal carcinoma: an endoscopist’s view. Clin Endosc. 2014;47:523–9.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TAR, Yerian L et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32:297–302.PubMedCrossRef Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TAR, Yerian L et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32:297–302.PubMedCrossRef
46.
Zurück zum Zitat Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201.PubMedCrossRef Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201.PubMedCrossRef
47.
Zurück zum Zitat Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83:248–52.PubMedCrossRef Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83:248–52.PubMedCrossRef
48.
Zurück zum Zitat Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG. Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg. 2010;14:462–9.PubMedCrossRef Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG. Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg. 2010;14:462–9.PubMedCrossRef
49.
Zurück zum Zitat Luc G, Durand M, Chiche L, Collet D. Major post-operative complications predict long-term survival after esophagectomy in patients with adenocarcinoma of the esophagus. World J Surg. 2015;39:216–22.PubMedCrossRef Luc G, Durand M, Chiche L, Collet D. Major post-operative complications predict long-term survival after esophagectomy in patients with adenocarcinoma of the esophagus. World J Surg. 2015;39:216–22.PubMedCrossRef
50.
Zurück zum Zitat Rizk NP, Bach PB, Schrag D, Bains MS, Turnbull AD, Karpeh M et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004;198:42–50.PubMedCrossRef Rizk NP, Bach PB, Schrag D, Bains MS, Turnbull AD, Karpeh M et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004;198:42–50.PubMedCrossRef
51.
Zurück zum Zitat Balta S, Cakar M, Demirkol S, Arslan Z, Akhan M. Higher neutrophil to lymhocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost. 2013;19:579.PubMedCrossRef Balta S, Cakar M, Demirkol S, Arslan Z, Akhan M. Higher neutrophil to lymhocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost. 2013;19:579.PubMedCrossRef
52.
Zurück zum Zitat Karaman M, Balta S, Seyit Ahmet AY, Cakar M, Naharci I, Demirkol S et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2013;35:516–22.PubMedCrossRef Karaman M, Balta S, Seyit Ahmet AY, Cakar M, Naharci I, Demirkol S et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2013;35:516–22.PubMedCrossRef
53.
Zurück zum Zitat Malietzis G, Giacometti M, Kennedy RH, Athanasiou T, Aziz O, Jenkins JT. The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21:3938–46.PubMedCrossRef Malietzis G, Giacometti M, Kennedy RH, Athanasiou T, Aziz O, Jenkins JT. The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21:3938–46.PubMedCrossRef
Metadaten
Titel
Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis
verfasst von
Hariruk Yodying, MD
Akihisa Matsuda, MD
Masao Miyashita, MD
Satoshi Matsumoto, MD
Nobuyuki Sakurazawa, MD
Marina Yamada, PhD
Eiji Uchida, MD
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4869-5

Weitere Artikel der Ausgabe 2/2016

Annals of Surgical Oncology 2/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.